Compare HTLD & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTLD | IMTX |
|---|---|---|
| Founded | 1978 | N/A |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 860.7M | 992.8M |
| IPO Year | 1995 | 2020 |
| Metric | HTLD | IMTX |
|---|---|---|
| Price | $10.15 | $6.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | $11.80 | ★ $15.97 |
| AVG Volume (30 Days) | 567.1K | ★ 1.0M |
| Earning Date | 10-20-2026 | 11-10-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $805,709,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.10 | $14.22 |
| P/E Ratio | $116.56 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.00 | $6.07 |
| 52 Week High | $16.64 | $12.41 |
| Indicator | HTLD | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.51 | 32.47 |
| Support Level | $9.94 | N/A |
| Resistance Level | $11.43 | $7.95 |
| Average True Range (ATR) | 0.42 | 0.46 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 14.70 | 4.10 |
Heartland Express Inc, along with its subsidiaries, operates as a short, medium, and long-haul truckload carrier and transportation services provider. It mainly provides nationwide asset-based dry van truckload service for shippers across the United States, along with cross-border freight and other transportation services offered through third-party partnerships in Mexico. The group operates under the brand names of Heartland Express, Millis Transfer, Smith Transport, and CFI (for services within Mexico).
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.